FRAPEJA PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
FRAPEJA PHARMA
Largest movements
- Tangible fixed assets -€24,573
down €24,573 (-8.6%), from €286,438 to €261,864
of which Other tangible fixed assets: -€34,731
- Receivables within one year +€20,863
up €20,863 (+17.5%), from €119,127 to €139,990
of which Trade receivables: +€19,732
- Intangible fixed assets -€11,949
down €11,949 (-33.1%), from €36,088 to €24,139
- Trade debts +€80,578
up €80,578 (+60.2%), from €133,907 to €214,485
- Debts after one year -€71,737
down €71,737 (-16.4%), from €437,810 to €366,073
of which Financial debts: -€45,583
- Profit (loss) carried forward -€37,162
down €37,162 (-7.8%), from -€476,866 to -€514,028
- Gross operating margin -€28,003
down €28,003 (-34.3%), from €81,631 to €53,628
- Financial income -€3,754
down €3,754 (-60.7%), from €6,184 to €2,430
- Depreciation +€2,544
up €2,544 (+3.8%), from €67,765 to €70,309
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €802,185 | €772,946 | -€29,239 | -3.6% |
| Fixed assets | 21/28 | €327,525 | €286,003 | -€41,522 | -12.7% |
| Intangible fixed assets | 21 | €36,088 | €24,139 | -€11,949 | -33.1% |
| Tangible fixed assets | 22/27 | €286,438 | €261,864 | -€24,573 | -8.6% |
| Plant, machinery and equipment | 23 | €33,761 | €28,115 | -€5,646 | -16.7% |
| Furniture and vehicles | 24 | - | €15,804 | +€15,804 | |
| Other tangible fixed assets | 26 | €252,677 | €217,946 | -€34,731 | -13.7% |
| Financial fixed assets | 28 | €5,000 | €0 | -€5,000 | -100% |
| Current assets | 29/58 | €474,660 | €486,943 | +€12,283 | +2.6% |
| Stocks and contracts in progress | 3 | €341,188 | €336,745 | -€4,444 | -1.3% |
| Stocks | 30/36 | €341,188 | €336,745 | -€4,444 | -1.3% |
| Amounts receivable within one year | 40/41 | €119,127 | €139,990 | +€20,863 | +17.5% |
| Trade receivables | 40 | €100,055 | €119,787 | +€19,732 | +19.7% |
| Other amounts receivable | 41 | €19,072 | €20,203 | +€1,131 | +5.9% |
| Cash at bank and in hand | 54/58 | €6,425 | €6,780 | +€355 | +5.5% |
| Deferred charges and accrued income | 490/1 | €7,920 | €3,428 | -€4,492 | -56.7% |
| Total equity and liabilities | 10/49 | €802,185 | €772,946 | -€29,239 | -3.6% |
| Equity | 10/15 | €173,134 | €135,972 | -€37,162 | -21.5% |
| Contributions | 10/11 | €650,000 | €650,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€476,866 | -€514,028 | -€37,162 | -7.8% |
| Amounts payable | 17/49 | €629,051 | €636,974 | +€7,923 | +1.3% |
| Amounts payable after more than one year | 17 | €437,810 | €366,073 | -€71,737 | -16.4% |
| Financial debts | 170/4 | €270,200 | €224,617 | -€45,583 | -16.9% |
| Other amounts payable | 178/9 | €167,610 | €141,456 | -€26,154 | -15.6% |
| Amounts payable within one year | 42/48 | €182,561 | €261,935 | +€79,374 | +43.5% |
| Current portion of amounts payable after more than one year | 42 | €43,910 | €45,583 | +€1,674 | +3.8% |
| Financial debts | 43 | - | €48 | +€48 | |
| Credit institutions | 430/8 | - | €48 | +€48 | |
| Trade debts | 44 | €133,907 | €214,485 | +€80,578 | +60.2% |
| Suppliers | 440/4 | €133,907 | €214,485 | +€80,578 | +60.2% |
| Taxes, remuneration and social security | 45 | €4,744 | €1,818 | -€2,926 | -61.7% |
| Taxes | 450/3 | €4,744 | €1,818 | -€2,926 | -61.7% |
| Accrued charges and deferred income | 492/3 | €8,680 | €8,967 | +€287 | +3.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €67,765 | €70,309 | +€2,544 | +3.8% |
| Other operating charges | 640/8 | €3,454 | €3,356 | -€98 | -2.8% |
| Gross operating margin | 9900 | €81,631 | €53,628 | -€28,003 | -34.3% |
| Operating profit (loss) | 9901 | €10,412 | -€20,038 | -€30,449 | |
| Financial income | 75/76B | €6,184 | €2,430 | -€3,754 | -60.7% |
| Recurring financial income | 75 | €6,184 | €2,430 | -€3,754 | -60.7% |
| Financial charges | 65/66B | €20,112 | €19,554 | -€558 | -2.8% |
| Recurring financial charges | 65 | €20,112 | €19,554 | -€558 | -2.8% |
| Profit (loss) for the period before taxes | 9903 | -€3,517 | -€37,162 | -€33,645 | -957% |
| Profit (loss) for the period | 9904 | -€3,517 | -€37,162 | -€33,645 | -957% |
| Profit (loss) for the period to be appropriated | 9905 | -€3,517 | -€37,162 | -€33,645 | -957% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 16 October 2026 via checked.be.